Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01766401 · ClinicalTrials.gov registry record · Phase 3
Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT01766401: Completed Phase 3 study, sponsored by Forest Laboratories.
NCT01766401 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 402 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01766401, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
Primary Outcome
The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered scale which consists of 14 items, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The highest possible score is 56, which represents the most severe form of anxiety; the lowest possible score is 0, which represents an absence of anxiety.
Interventions
- DRUG Placebo
- DRUG Vilazadone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2013-01-31 |
| Est. Completion | 2014-01-29 |
| Phase | Phase 3 |
What the finished NCT01766401 record still lists
NCT01766401 is an interventional study that assigns participants to a tested intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01766401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01766401 about?
NCT01766401 is a clinical study titled "Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder". The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
What is the current status of trial NCT01766401?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2013-01-31. Estimated completion is 2014-01-29.
What interventions are being tested in trial NCT01766401?
The interventions under investigation include: Placebo (DRUG), Vilazadone (DRUG).
Who is sponsoring clinical trial NCT01766401?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01766401's enrollment target sits among peer trials
402 919th of 2000 higher than 1,080 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI